Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.57 |
| ▸ | GAPDH | P04406 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | HRAS | P01112 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886712 | 1.00 | MEN1 (0.61) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL9223575 | 1.00 | MEN1 (0.61) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL8591286 | 1.00 | MEN1 (0.61) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL1882384 | 1.00 | MEN1 (0.61) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL14428953 | 0.99 | MEN1 (0.60) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL30976646 | 0.96 | MEN1 (0.60) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL9131765 | 0.95 | MEN1 (0.56) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL19132202 | 0.95 | MEN1 (0.56) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL16907939 | 0.95 | MEN1 (0.56) | MEN1USP2POLBKMT2ARNASE1 | |
| SCHEMBL15691494 | 0.95 | MEN1 (0.56) | MEN1USP2POLBKMT2ARNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | MEN1 3823/4885USP2 3140/4885POLB 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.